Abstract
Recent evidence has linked striatalN-methyl-d-aspartate (NMDA) receptor function to the adverse effects of long-term dopaminergic treatment in Parkinson's disease. We have studied the abundance, composition, and phosphorylation of NMDA receptor subunits (NRs) in the rat 6-hydroxydopamine lesion model of parkinsonism. In lesioned striatum, the abundance of NR1 and NR2B in striatal membranes was decreased to 68 ± 3.2 and 62 ± 4.4%, respectively, relative to the unlesioned striata, whereas the abundance of NR2A was unchanged. Coimmunoprecipitation of NMDA receptors under nondenaturing conditions revealed that these changes reflected a selective depletion of receptors composed of NR1/NR2B, without alteration in receptors composed of NR1/NR2A. However, the abundance and composition of striatal NMDA receptors in extracts containing both cytoplasmic and membrane proteins were not altered in lesioned rats, suggesting that the changes in the membrane fraction resulted from intracellular redistribution of receptors. The phosphorylation of NR1 protein at serine 890 and serine 896, but not at serine 897, and the tyrosine phosphorylation of NR2B but not NR2A were decreased in the membrane fraction of the lesioned striatum. Chronic treatment of lesioned rats with l-dopa normalized the alterations in the abundance and subunit composition of the NMDA receptors in striatal membranes, and produced striking hyperphosphorylation, both of NR1 at serine residues, and NR2A and NR2B at tyrosine residues. These findings suggest that the adverse motor effects of chronic l-dopa therapy may result from alterations in regulatory phosphorylation sites on NMDA receptors.
Footnotes
-
Send reprint requests to: Dr. David G. Standaert, Department of Neurology, Warren 408, Massachusetts General Hospital, 32 Fruit St., Boston, MA 02114. E-mail: standaert{at}helix.mgh.harvard.edu
-
This research was supported by Grants from the National Institutes of Health NS31579 and NS34361 (to D.G.S.), NS2830 (to B.B.W.), a Cotzias Fellowship from The American Parkinson Disease Association (to D.G.S.), and a grant from The National Parkinson Foundation (to A.W.D.).
- Abbreviations:
- 6-OHDA
- 6-hydroxydopamine
- NMDA
- N-methyl-d-aspartate
- NR
- NMDA receptor subunit
- RT
- room temperature
- PAGE
- polyacrylamide gel electrophoresis
- PVDF
- polyvinylidene difluoride
- Received September 2, 1999.
- Accepted October 28, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|